Step 1 topics → Renal → Potassium-Sparing Diuretics

Potassium-Sparing Diuretics

USMLE Step 1 trap: Confuses ENaC blockers (amiloride, triamterene) with MRAs (spironolactone, eplerenone), missing their distinct mechanisms. Spironolactone and eplerenone are mineralocorticoid receptor antagonists, while amiloride and triamterene directly block ENaC channels independent of aldosterone.

Potassium-sparing diuretics are a small class with two mechanistically distinct subgroups, and USMLE Step 1 loves to exploit that distinction. The mineralocorticoid receptor antagonists (MRAs) — spironolactone and eplerenone — block aldosterone's receptor in the collecting duct, preventing transcription of ENaC and Na/K-ATPase. The ENaC blockers — amiloride and triamterene — skip aldosterone entirely and directly plug the sodium channel. Both groups reduce sodium reabsorption and potassium secretion in the principal cells of the collecting duct, but their upstream mechanisms are completely different.

The exam tests this class at three levels: pure mechanism recall (which drug does what), clinical application (when to use which agent and why), and adverse effect attribution (which side effects belong to which drug). The trickiest part is that students often treat all potassium-sparing diuretics as interchangeable. They're not. Spironolactone has anti-androgenic effects because it binds progesterone and androgen receptors nonselectively — eplerenone was designed to avoid exactly that. Amiloride and triamterene have zero hormonal activity. Getting this wrong on a vignette means misidentifying a drug's side effect profile or choosing the wrong agent for a clinical scenario.

Beyond basic mechanism, USMLE Step 1 also probes the clinical roles that students often under-learn: spironolactone is first-line for primary hyperaldosteronism (Conn syndrome) and has a proven mortality benefit in heart failure with reduced ejection fraction — a benefit that goes beyond just diuresis. If you only know these drugs as 'weak diuretics that spare potassium,' you'll miss those application questions cold.

From real student decks
76%have cards covering this topic
57%have mature cards

Common misconceptions

Common mistake
Wrong: All potassium-sparing diuretics work by blocking aldosterone receptors.
Right: Spironolactone and eplerenone are mineralocorticoid receptor antagonists, while amiloride and triamterene directly block ENaC channels independent of aldosterone.
Amiloride and triamterene do not interact with aldosterone or its receptor at all — they physically block ENaC in the luminal membrane of principal cells, so their effect is the same whether aldosterone is high, low, or absent. This matters clinically: in a patient with low aldosterone (e.g., on ACE inhibitor), ENaC blockers still work, while MRAs have less substrate to antagonize. When you see a vignette describing a drug that 'directly blocks sodium channels in the collecting duct,' that's your cue it's amiloride or triamterene, not spironolactone.
Common mistake
Wrong: Spironolactone's anti-androgenic side effects (gynecomastia, menstrual irregularities) occur with all potassium-sparing diuretics.
Right: Anti-androgenic side effects are specific to spironolactone due to its non-selective steroid receptor binding; eplerenone is more selective and lacks these effects, while ENaC blockers have no hormonal activity.
Spironolactone's gynecomastia and menstrual irregularities come from its promiscuous binding to androgen and progesterone receptors — it's a steroidal compound with poor receptor selectivity. Eplerenone has a modified structure that gives it much higher mineralocorticoid receptor selectivity, so it doesn't cause these hormonal side effects. Amiloride and triamterene are not steroid-based at all and have no hormonal receptor activity whatsoever. If a vignette gives you a male patient on a potassium-sparing diuretic developing gynecomastia, the answer is spironolactone specifically — not the class.
Common mistake
Gap: Missing the dual role of spironolactone in primary hyperaldosteronism and heart failure mortality reduction
Spironolactone is the drug of choice for primary hyperaldosteronism (Conn syndrome) and also has mortality benefit in heart failure with reduced ejection fraction independent of its diuretic effect.
Spironolactone is the pharmacological treatment of choice for primary hyperaldosteronism because it directly antagonizes the excess aldosterone driving the pathology — it treats the mechanism, not just the symptoms. Separately, in heart failure with reduced ejection fraction, aldosterone causes myocardial fibrosis and remodeling; MRAs reduce mortality by blocking this effect, which is independent of their diuretic action. Students who only think of these as 'weak diuretics' miss both of these high-yield use cases, especially the HFrEF mortality benefit which the exam likes to test alongside ACE inhibitors and beta-blockers.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the two mechanistic classes: MRAs (spironolactone, eplerenone) block the aldosterone receptor, while ENaC blockers (amiloride, triamterene) directly inhibit the sodium channel regardless of aldosterone levels — and be able to identify which class a drug belongs to based on its mechanism description.
  2. Know the clinical indications: spironolactone for primary hyperaldosteronism, heart failure with reduced ejection fraction (mortality benefit), cirrhotic ascites, and resistant hypertension; eplerenone post-MI with reduced EF; amiloride or triamterene as add-ons when potassium preservation is needed without hormonal effects.
  3. Know which adverse effects belong to which drug: hyperkalemia applies to the entire class, but gynecomastia, menstrual irregularities, and decreased libido are spironolactone-specific; eplerenone avoids these hormonal side effects by design; ENaC blockers cause neither hormonal effects nor the MRA-specific issues.

Can you avoid these mistakes?

A patient with Conn syndrome (primary hyperaldosteronism) is started on a drug that competitively blocks aldosterone's intracellular receptor. Six months later he develops gynecomastia. Which drug is this, and why does this side effect occur — and which drug in the same mechanistic class would avoid this effect?
A patient with cirrhosis and ascites is on spironolactone. Her potassium is now 6.1 mEq/L. You want to switch to a potassium-sparing diuretic that does NOT work through the aldosterone receptor. Which drug would you choose, and at what site in the nephron does it act?
A patient with heart failure and EF of 30% is already on lisinopril and metoprolol. You add spironolactone. A classmate says 'that's just for extra diuresis.' What's the more important reason to add it, and what evidence-based benefit does it provide beyond fluid removal?
Amiloride is given to a patient with very low aldosterone levels (e.g., hypoaldosteronism). Will it still reduce potassium excretion? Compare this to what would happen if you gave spironolactone to the same patient, and explain the difference based on mechanism.

Related topics

Collecting Duct Transport Renin-Angiotensin-Aldosterone System Kidney Development (Pro-/Meso-/Metanephros) Congenital Renal Anomalies Nephron Structure and Segments Renal Vasculature (Afferent / Efferent / Vasa Recta)

See how your Anki deck covers this topic.

Upload your deck for a free audit →